Benralizumab for the treatment of severe eosinophilic asthma

Benralizumab (Fasenra) is a new anti-interleukin-5 monoclonal antibody therapy for the management of severe uncontrolled eosinophilic asthma. This article discusses its properties, clinical trial efficacy and adverse effects.

Read the full article

Add yours ↓
Web design and marketing agency Leamington Spa